Data as of Apr 17
| -0.35 / -0.25%|
The 24 analysts offering 12-month price forecasts for Celgene Corp have a median target of 192.00, with a high estimate of 248.00 and a low estimate of 134.00. The median estimate represents a +35.68% increase from the last price of 141.51.
The current consensus among 29 polled investment analysts is to Buy stock in Celgene Corp. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.